Edition:
United Kingdom

UCB Phase 2B Study Of DZP In SLE: Primary Endpoint Not Met


Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - UCB SA ::TOPLINE RESULTS FROM A PHASE 2B STUDY OF DAPIROLIZUMAB PEGOL IN SLE.PRIMARY ENDPOINT OF THE STUDY WAS NOT MET.STUDY DID DEMONSTRATE CONSISTENT AND POTENTIALLY MEANINGFUL IMPROVEMENTS FOR THE MAJORITY OF CLINICAL ENDPOINTS IN PATIENTS TREATED WITH DZP COMPARED WITH PLACEBO.DZP WAS WELL TOLERATED AND DEMONSTRATED AN ACCEPTABLE SAFETY PROFILE..BIOMARKER DATA DEMONSTRATED EVIDENCE OF PROOF OF BIOLOGY..